Avita is not a one trick pony like most medical device company's, that is why they have to undertake multiple clinical trials to prove its efficacy for each individual indication and doing these at the same time is costly at the early stages of the product development.
What gives me confidence is that I see these multiple clinical trials as one off expenses and once approved will provide Avita multiple extra revenue streams. Also all of the indications Avitia is perusing is de risked and proven to work.
In regards to growth currently Avita is only in the adult inpatient burns segment with is the smallest market that they are perusing and even if they gain 50% uptake of the total market that is a lot of revenue.
Avita is not a one trick pony like most medical device...
-
- There are more pages in this discussion • 594 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.76 |
Change
0.130(4.94%) |
Mkt cap ! $187.9M | |||
| Open | High | Low | Value | Volume |
| $2.74 | $2.77 | $2.66 | $1.044M | 382.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 980 | $2.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.76 | 10173 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |